<2> Galleri Cancer Tests: Controversial NHS Trial Fails to Meet Key Goal
<3> Background on Galleri Cancer Tests
The Galleri cancer test, developed by US-based company Grail, has been a subject of interest and controversy in the medical community. This blood test promises to detect multiple cancers in their early stages, using sequencing technology to analyze DNA fragments circulating in the blood, also known as cell-free DNA (cfDNA). The test aims to identify more than 50 cancers in a single sample, making it a promising tool for early cancer detection.
<3> The NHS-Galleri Trial
In 2020, Grail announced that it would fund a £150m trial of the Galleri test in the UK, in collaboration with the National Health Service (NHS). The trial, known as the NHS-Galleri trial, aimed to evaluate the effectiveness of the test in detecting cancers at an early stage. However, recent results from the trial have raised concerns about the test’s ability to meet its key endpoint.
<3> Trial Results
According to recent reports, the NHS-Galleri trial failed to meet its key endpoint of a significant reduction in stage III-IV cases. This means that the test